Novartis' Adakveo, or crizanlizumab, has been approved by the European Commission in combination with hydroxyurea for the prevention of recurrent painful vaso-occlusive crises in people with sickle cell disease ages 16 and older.
EU OKs crizanlizumab to prevent sickle cell disease pain
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.